2025 Pitchers

Home » 2025 Pitchers

Start-up Slams

Tuesday, December 2^nd | 10.00 – 11.00 am

ENABLING TECHNOLOGIES

EVERSYN Stand IA8
Glycans – Cell-free biosynthesis – Glycoengineering

ZERION PHARMA Stand H16
Dispersome – Solubility enhancer – Bioavailability

IASO DISCOVERY Stand F1
Oligonucleotides therapeutics – Technological platform – Drug discovery

BIOLLIGENCE Stand IA6
Explainable AI – Population level toxicity – Artificial Intelligence

Tuesday, December 2^nd | 2.00 – 3.30 pm

RARE DISEASES

REVENTUS PHARMA Stand IA17
Mitochondrial diseases – Derisked clinical development – Drug repositioning

CURLIM
Peripheral neuropathies – Platform – Charcot-Marie-Tooth

INFECTIOUS DISEASES

SPYDIAG Stand IA18
BK virus – Kidney transplant – Therapy diagnostics

HERMIONE THERAPEUTICS Stand IA10
Biofilm dispersion – Boost antibiotics – Prevent ATB escalation

DIAGNOSTICS | PREVENTION

NAWU DIAGNOSTICS Stand IA26 – MedFIT Innov’Area
Point-of-care – Diagnostics – Lab-on-chip

YOU2YOURSELF Stand IA20
Health monitoring – MicroRNA’s – Urine

Tuesday, December 2^nd | 4.45 – 6.00 pm

CELL & GENE THERAPY

HARMONIX Stand IA9
Mitochondrial diseases – Derisked clinical development – Drug repositioning

ORAGEN THERAPEUTICS Stand IA15
Delivery – Genetic – IBD

MAGNOSTICS Stand IA13
Gene therapy – Nucleic Acid – Separation

ABLEVIA BIOTECH Stand IA1
Enabling drug – Anti-drug antibody removal – LNP, PEGalted drugs

EPITOME THERAPEUTICS FLEXCO Stand IA7
Epigenome – Advanced Therapies – CRISPR/Cas

Wednesday, December 3^rd | 11.30 am – 12.30 pm

ONCOLOGY

ABTX Stand IA2
Fragment ADC – Pancreatic cancer – Transglutaminase

YOMI PHARMA Stand IA19
Lung cancer – Peptide – Targeted therapy

KLASTHER BIOPHARMA Stand IA12
Cancer therapeutics – Warburg effect – ADCs and RACs

PERSEA Stand IA16
CGT – Solid cancers – Targeted treatment

Wednesday, December 3^rd | 2.00 – 3.00 pm

CNS

AMPORIN PHARMACEUTICALS Stand IA4
Small molecule drugs – Neurodegenerative diseases – Disease-modifying treatments

ARPHAMID THERAPEUTICS Stand IA5
Opioid tolerance/hyperalgesia – Breakthrough pain in cancer – Novel non-opioid therapeutics

INNOVADE THERAPEUTICS Stand IA11
Depression – Rapid Acting Antidepressant – Synaptic plasticity

ALLOTHERA Stand IA3
Neuro – Pain – Biotech

Collaborative and Licensing Opportunity Presentations

Tuesday, December 2^nd | 11.00 am – 12.30 pm

CELL & GENE THERAPY

FONDAZIONE TELETHON
Mutation Independent Gene Therapy – Large genes – Genetic diseases

FONDAZIONE TELETHON
In vivo gene therapy – Hematopoietic stem cells (HSCs) – Phagocytosis-shielded LV

UNISMART (FONDAZIONE UNIVERSITA DI PADOVA) – TREM2MEDS
Alzheimer’s disease – Gene therapy – Cell therapy

DRUG DELIVERY

BIO-SOURCING – ORALIMUMAB AND TRASTUSORAL
Monoclonal antibodies – Oral delivery – Biosimilars

Wednesday, December 3^rd | 9.15 - 11.00 am

ONCOLOGY | IMMUNO-ONCOLOGY

IOCB TECH
Sting – Oncology – ADC

ISTITUTO EUROPEO DI ONCOLOGIA – FLACHIMMUNE
Microbioma – Therapeutic vaccine peptides – Tumor

DERMATOLOGY

UNIVERSITY OF PORTO – SKINGUARD53-VITD
Skin cancer prevention – Mutant p53 reactivation – Topical nanoformulation

UNIVERSITY OF PORTO – PEPILSKIN
Wound-healing – Antimicrobial – Diabetic foot ulcer

DRUG DISCOVERY

NEBULA – GENAI CONF
Drug discovery – Artificial Intelligence – Enabling technology

SATT CONECTUS – TURN-ON
Imaging – GPCR – Drug discovery

CARDIOMETABOLIC DISEASES

EFS (ETABLISSEMENT FRANCAIS DU SANG)
Antibody-Drug Conjugate – Anticoagulation – Thrombosis

Animal Health Presentations

Co-organised by: within

Supported by:

Tuesday, December 2^nd | 3.45 – 4.30 pm

UNIVERSITY OF PORTO
Diabetes – Gastrointestinal – Renin-angiotensin-aldosterone system

GHENT UNIVERSITY – MUCOVAC
Oral immunisation – Targeted delivery – Platform technology

BIOAZ
Immunocastration – Nanobodies – Gene therapy

IC BIOSOLUTIONS
iPS (induced pluripotent stem cells) – Secretome – Off-the-shelf

Farzad Abdi-Dezfuli, Partner, Sarsia
Sofia Arnal, Associate, AdBio Partners
Juri Bach, Senior Investment Manager, High-Tech Gründerfonds
Jürgen Bauer, Deputy Managing Director, EMBLEM Technology Transfer
Fadwa Benkessou, Academia-Industry Alliance Manager, Karolinska Institutet
Leonardo Biondi, CEO, Biondi
Jean-Luc Chagnaud, Head of Business Development in Health Innovations, Aquitaine Science Transfert
Martial Descoutures, Head of Pharma and Biotech/Medtech, Corporates & Markets, ODDO BHF
Guy Hélin, CEO, Syngulon
Andreas Kastenbauer, Partner, MIG Capital
Esther Lange, BD Manager Viral Vector Out-Licensing, Revvity
Radoslaw Lipinski, Deputy Head Partnership CNS and NCE, Global BD&L, Boehringer Ingelheim
Julie Proft, Head of Project Management, IOCB Tech
Nicolas Roberti de Winghe, Managing Partner, TCD Capital
Stefan Savic, CEO, LIFE BioCEEd
Daniel Sieiro, Associate, Sofinnova Partners
Yannick Vancoppenolle, Partner, Vives Partners
Giulia Vestri, Partner, Claris Ventures
Joachim Vogt, Director Search and Evaluation, International, Abbvie
Anela Vukoja, Life Sciences investor
Jean-Pascal Marc, General Manager, Ceanothus Consulting
Steve Nanchen, Senior Director – Head External Innovation, Elanco Animal Health
Eduardo De Oliveira Pontes, Director Research Alliances – External Innovation, Zoetis
Hervé Poulet, Senior Director, Strategic Partnering, Boehringer Ingelheim Animal Health
Edouard Timsit, Director of Global Innovation Livestock Health and Sustainability, Ceva Animal Health